n May 2013, Drs. Madsen and Labhasetwar formed this wholly owned subsidiary to commercialize the patented nanoparticles in the topical application market – sun care, skincare, and cosmetics. The company is currently performing testing of the ability of Pro-NP™ to control free radical formation in skin tissue upon exposure to UV rays.
roTransit has formed this wholly owned subsidiary to expand the applications into spinal cord therapy. Spinal Therapy will develop, license and sell its proprietary nanoparticle delivery system loaded with a powerful blend of antioxidants (Pro-NP™) first into the veterinarian market and then the human market for acute spinal cord injury.